ArticleFrontiers in oncology2025
Clinical comparison of radiofrequency ablation and surgical resection in treating pulmonar metastasis of hepatoblastoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the efficacy variances between radiofrequency ablation and traditional surgical resection in treating pulmonary metastasis of hepatoblastoma in children, and to provide more feasible methods for the treatment of this disease. Methods: A total of 91 pediatric hepatoblastoma (HB) patients with pulmonary metastases, admitted to Shandong Cancer Hospital between Sept. 2021 and Oct. 2023, were enrolled in this study. Among them, 31 received radiofrequency ablation for pulmonary metastasis eradication, while 60 underwent surgical resection to remove the pulmonary metastases. To assess the comparative effectiveness of these two interventional approaches in treating pediatric pulmonary metastases from hepatoblastoma, differences between the two groups were analyzed in terms of alpha-fetoprotein (AFP) levels, complication rates, antibiotic use, operative duration, length of hospital stay, and hospitalization costs. Results: The average levels of AFP in both the radiofrequency ablation group and the surgical resection group decreased significantly after treatment, with no statistical significance between the groups ( Conclusion: Radiofrequency ablation for HB pulmonary metastases is more feasible, safer, and cost-effective due to its advantages of less invasive and painful, faster recovery, economical, and lower adjacent complication rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.